Differentiating pulmonary transfusion reactions using recipient and transfusion factors

Transfusion

Volumn 57, Issue 7, 2017, Pages 1684-1690

  Roubinian, Nareg H ^a,b   Looney, Mark R ^b   Keating, Sheila ^a   Kor, Daryl J ^c   Lowell, Clifford A ^a   Gajic, Ognjen ^c   Hubmayr, Rolf ^c   Gropper, Michael ^b   Koenigsberg, Monique ^b   Wilson, Gregory A ^c   A Matthay, Michael ^b   Toy, Pearl ^b   Murphy, Edward L ^a,b  

^a BLOOD SYSTEMS RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN 2; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CYSTATIN C; GROWTH DIFFERENTIATION FACTOR 15; HYPERTENSIVE FACTOR; ST 2 PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD TRANSFUSION; BLOOD TRANSFUSION REACTION; CASE CONTROL STUDY; CHRONIC KIDNEY FAILURE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; ERYTHROCYTE TRANSFUSION; FEMALE; HEMODIALYSIS; HUMAN; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PLASMA TRANSFUSION; POST HOC ANALYSIS; RECIPIENT; THROMBOCYTE TRANSFUSION; TRANSFUSION ASSOCIATED CIRCULATORY OVERLOAD; TRANSFUSION RELATED ACUTE LUNG INJURY; ACUTE LUNG INJURY; AGED; BLOOD; MIDDLE AGED; STATISTICAL MODEL; TRANSFUSION REACTION;

ACUTE LUNG INJURY; ADULT; AGED; FEMALE; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; TRANSFUSION REACTION;

EID: 85018772447     PISSN: 00411132     EISSN: 15372995     Source Type: Journal    
DOI: 10.1111/trf.14118     Document Type: Article

References (33)

1. Popovsky MA. Pulmonary consequences of transfusion: TRALI and TACO. Transfus Apher Sci 2006;34:243-4.
2. Looney MR, Roubinian N, Gajic O, et al. Prospective study on the clinical course and outcomes in transfusion-related acute lung injury*. Crit Care Med 2014;42:1676-87.
3. Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. Blood 2012;119:1757-67.
4. Kleinman SH, Triulzi DJ, Murphy EL, et al. The Leukocyte Antibody Prevalence Study-II (LAPS-II): a retrospective cohort study of transfusion-related acute lung injury in recipients of high-plasma-volume human leukocyte antigen antibody-positive or -negative components. Transfusion 2011;51:2078-91.
5. van Stein D, Beckers EA, Sintnicolaas K, et al. Transfusion-related acute lung injury reports in the Netherlands: an observational study. Transfusion 2010;50:213-20.
6. Hashimoto S, Nakajima F, Kamada H, et al. Relationship of donor HLA antibody strength to the development of transfusion-related acute lung injury. Transfusion 2010;50:2582-91.
7. Skeate RC, Eastlund T. Distinguishing between transfusion related acute lung injury and transfusion associated circulatory overload. Curr Opin Hematol 2007;14:682-7.
8. Gajic O, Gropper MA, Hubmayr RD. Pulmonary edema after transfusion: how to differentiate transfusion-associated circulatory overload from transfusion-related acute lung injury. Crit Care Med 2006;34(5Suppl):S109-13.
9. Vlaar AP, Hofstra JJ, Determann RM, et al. Transfusion-related acute lung injury in cardiac surgery patients is characterized by pulmonary inflammation and coagulopathy: a prospective nested case-control study. Crit Care Med 2012;40:2813-20.
10. Roubinian NH, Looney MR, Kor DJ, et al. Cytokines and clinical predictors in distinguishing pulmonary transfusion reactions. Transfusion 2015;55:1838-46.
11. Tobian AA, Sokoll LJ, Tisch DJ, et al. N-terminal pro-brain natriuretic peptide is a useful diagnostic marker for transfusion-associated circulatory overload. Transfusion 2008;48:1143-50.
12. Zhou L, Giacherio D, Cooling L, et al. Use of B-natriuretic peptide as a diagnostic marker in the differential diagnosis of transfusion-associated circulatory overload. Transfusion 2005;45:1056-63.
13. Li G, Daniels CE, Kojicic M, et al. The accuracy of natriuretic peptides (brain natriuretic peptide and N-terminal pro-brain natriuretic) in the differentiation between transfusion-related acute lung injury and transfusion-related circulatory overload in the critically ill. Transfusion 2009;49:13-20.
14. Finlay HE, Cassorla L, Feiner J, et al. Designing and testing a computer-based screening system for transfusion-related acute lung injury. Am J Clin Pathol 2005;124:601-9.
15. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005;33:721-6.
16. Division of Health Quality Promotion, National Center for Preparedness Detection, and Control of Infectious Diseases, Centers for Disease Control and Prevention. The National Healthcare Safety Network (NHSN) Manual Biovigilance Component Protocol, Hemovigilance Module. Atlanta: Centers for Disease Control and Prevention; 2009.
17. Murphy EL, Kwaan N, Looney MR, et al. Risk factors and outcomes in transfusion-associated circulatory overload. Am J Med 2013;126:357 e29-38.
18. Wiedemann HP, Wheeler AP, Bernard GR, et al. Comparison of two fluid-management strategies in acute lung injury. N Engl J Med 2006;354:2564-75.
19. Semler MW, Marney AM, Rice TW, et al. B-type natriuretic peptide, aldosterone, and fluid management in ARDS. Chest 2016;150:102-11.
20. Toy P, Kleinman SH, Looney MR. Proposed revised nomenclature for transfusion-related acute lung injury. Transfusion 2016;56:709-13.
21. Famous KR, Delucchi K, Ware LB, et al. Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med 2017;195:331-8.
22. Calfee CS, Delucchi K, Parsons PE, et al. Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med 2014;2:611-20.
23. Lannan KL, Sahler J, Spinelli SL, et al. Transfusion immunomodulation—the case for leukoreduced and (perhaps) washed transfusions. Blood Cells Mol Dis 2013;50:61-8.
24. Vickery S, Price CP, John RI, et al. B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with CKD: relationship to renal function and left ventricular hypertrophy. Am J Kidney Dis 2005;46:610-20.
25. Das SR, Drazner MH, Dries DL, et al. Impact of body mass and body composition on circulating levels of natriuretic peptides: results from the Dallas Heart Study. Circulation 2005;112:2163-8.
26. Watt DG, Horgan PG, McMillan DC. Routine clinical markers of the magnitude of the systemic inflammatory response after elective operation: a systematic review. Surgery 2015;157:362-80.
27. Agrawal A, Matthay MA, Kangelaris KN, et al. Plasma angiopoietin-2 predicts the onset of acute lung injury in critically ill patients. Am J Respir Crit Care Med 2013;187:736-42.
28. Shah KS, Maisel AS. Novel biomarkers in heart failure with preserved ejection fraction. Heart Fail Clin 2014;10:471-9.
29. Arpino V, Mehta S, Wang L, et al. Tissue inhibitor of metalloproteinases 3-dependent microvascular endothelial cell barrier function is disrupted under septic conditions. Am J Physiol Heart Circ Physiol 2016;310:H1455-67.
30. Clifford L, Jia Q, Subramanian A, et al. Characterizing the epidemiology of postoperative transfusion-related acute lung injury. Anesthesiology 2015;122:12-20.
31. Clifford L, Singh A, Wilson GA, et al. Electronic health record surveillance algorithms facilitate the detection of transfusion-related pulmonary complications. Transfusion 2013;53:1205-16.
32. Transfusion-associated circulatory overload (TACO) 2014 revision. International Society of Blood Transfusion Working Party on Haemovigilance in collaboration with The International Haemovigilance Network Prepublication Draft December 2014 [Internet]. Amsterdam: ISBT Central Office; 2014 [cited 2016 Aug 30]. http://www.isbtweb.org/fileadmin/user_upload/files-2015/haemovigilance/TACO_definition_validation_form_jan2015_haemovigilance.pdf.
33. Proposed standard definitions for surveillance of non infectious adverse transfusion reactions. International Society of Blood Transfusion Working Party on Haemovigilance in collaboration with The International Haemovigilance Network July 2011 [cited 2016 Aug 30]. http://www.isbtweb.org/fileadmin/user_upload/files-2015/haemovigilance/definitions/Proposed%20definitions%202011%20surveillance%20non%20infectious%20adverse%20reactions%20haemovigilance%20incl%20TRALI%20correction%202013.pdf.